#USA #New York #Levi & Korsinsky #Securities Fraud #aTyr Pharma

Overview

Levi & Korsinsky, LLP has announced a significant class action lawsuit involving aTyr Pharma, Inc., noted by its NASDAQ ticker symbol ATYR. This lawsuit is crucial for investors as it seeks to address alleged securities fraud that affected many shareholders in the company during a specific time frame.

Class Action Lawsuit Details

The lawsuit aims to recover financial losses for investors who were impacted by the misleading information disseminated by aTyr's management. These alleged actions occurred between January 16, 2025, and September 12, 2025. Investors are encouraged to follow the guidelines provided by the law firm, and they have until December 8, 2025, to apply to become a lead plaintiff in this lawsuit.

Allegations Against aTyr Pharma

The complaint alleges that aTyr's executives continuously presented optimistic information regarding the company's drug, Efzofitimod, while intentionally downplaying or hiding pertinent adverse facts. Specifically, these statements exaggerate the drug's capability to allow patients to taper off steroid usage completely. On September 15, 2025, aTyr's investor call exposed the truth; the EFZO-FIT study failed to reach its primary endpoint, disappointing both the company and its investors. Stock prices plummeted from a closing value of around $6.03 per share to $1.02, marking a staggering 83.2% drop in just one day.

Next Steps for Investors

If you are an affected shareholder, it's critical to act swiftly. For those who experienced financial losses within the set timeframe, the opportunity exists to request to be appointed as a lead plaintiff. However, it’s important to note that you don't need to be a lead plaintiff to receive compensation.

No Financial Burden for Class Members

For affected individuals, it is essential to understand that participating in this lawsuit incurs no costs. If you qualify as a class member, reimbursement for any potential losses could come without any out-of-pocket expenses. Levi & Korsinsky assures that the financial aspects of joining this class action will not impose barriers on the investors who were affected.

Why Choose Levi & Korsinsky?

With an impressive track record spanning over two decades, Levi & Korsinsky has championed the rights of investors, securing millions in settlements for shareholders. The firm boasts a dedicated team of over 70 professionals who specialize in complex securities litigation. Their commitment has earned them recognition as one of the top litigation firms in the United States, particularly in the realm of securities class actions.

Contact Information

For further inquiries or to discuss your situation, reach out to:

• - Joseph E. Levi, Esq.
• - Ed Korsinsky, Esq.
• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

Ensure that your voice is heard in this critical period for aTyr Pharma investors. Stay informed and consider your options carefully as these legal proceedings continue to unfold.